Cold agglutinin disease and IgM mediated hemolysis are now treated with TARGETED therapy. Sutimlimab is C1 inhibitor.

No more useless steroids.

No more chemotherapy like cyclophosphamide.

No more non-specific therapy with Rituximab.

🚨Excited to share our lab’s latest papers in health decision science. First, in AmericanJournalofHematology, a Penn-Yale collab co-led by future MD Daniel Wang Yale School of Medicine: cost-effectiveness of sutimlimab in cold agglutinin disease
doi.org/10.1002/ajh.27…

The first randomized trial in cold agglutinin disease ever just got published: Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial ashpublications.org/blood/article/…

AIHA in ASH 2021:

- Sutimlimab (complement inhibitor)
Mainly in cold agglutinin disease

#BASH2021

داء الراصات الباردةCAD

🔴مرض مناعي نادر يهاجم فيه الجهاز المناعي كريات الدم الحمراء مسببا فقر دم

✅هيئة الغذاء والدواء U.S. FDA تعتمد دواء
💉Enjaymo™ (sutimlimab-jome)إنجايمو
كأول دواء لهذا المرض

⬇️خفض بيليروبين

⬆️عزز الهيموغلوبين و✅الكفاءة الجسدية
sanofi.com/en/media-room/…

A newly published case report suggests sutimlimab (Enjaymo) may be an effective treatment for some patients with warm #autoimmune hemolytic anemia (wAIHA). buff.ly/3bbjikB

【新着記事】

製薬業界 きょうのニュース
・サノフィ　寒冷凝集素症治療薬sutimlimabを日本で申請
・第一三共　視覚再生の遺伝子治療薬、名古屋工業大と共同研究
・ヘリオス、HLCM051のP2試験に新型コロナ肺炎患者を組み入れ
など

#AnswersNews
buff.ly/3erx7IC

A new study published in NEJM finds therapeutic effects of sutimlimab, a monoclonal antibody, for the treatment of cold agglutination disease. Read more at: bit.ly/sutimlimab #Blooducation #TransfusionMedicine #AutoimmuneDisease #MAbs AABB

New episode! Topics include sutimlimab vs placebo in cold agglutinin disease, the impact of etoposide versus auto-transplant in PTCL, and the role of pulmonary NETs in #SCD loom.ly/PFYhvZ8

Sutimlimab: C1 inhibitor for cold agglutinin disease
Pegcetacoplan: C 3 inhibitor for PNH
Avacopan: C5 inhibitor for PAN and vasculitis

This is interesting, not only because we may have a new class of drug for #ITP , but because it points to involvement of complement in its pathophysiology. Sutimlimab is a selective C1s classical Complement pathway blocker. tinyurl.com/bdde69m9

New ep this week! Topics include sutimlimab vs placebo in cold agglutinin disease, the impact of etoposide versus auto-transplant in PTCL, and the role of pulmonary NETs in sickle cell disease loom.ly/71P_axw

#Sutimlimab in patients with #ColdAgglutininDisease : Results of the randomized placebo-controlled phase 3 #CADENZA trial

Sutimlimab significantly increased mean hemoglobin!👇
bit.ly/3xHuX3a
Uniklinikum Essen🇩🇪| Michael Storek

CARDINAL study 1-year interim follow-up results reinforce the positive risk-benefit profile of sutimlimab as an effective long-term therapy with an acceptable safety profile for management of patients with chronic CAD.
haematologica.org/article/view/h…

#FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. sanofi.com/en/media-room/…

Sutimlimab in Cold Agglutinin Disease | NEJM nejm.org/doi/full/10.10…

Does sutimlimab have a CVR attached? Asking for a friend

FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
globenewswire.com/news-release/2…

Sutimlimab in Cold Agglutinin Disease | NEJM nejm.org/doi/10.1056/NE…

We expect a considerable number of questions on benign hematological disorders (i.e. not related to cancer). This is because a few novel, game changing drugs were recently introduced:

-Voxelotor
-Crizanlizumab
-Caplacizumab
-Pegcetacoplan
-Sutimlimab

Medque.st/PharmQBank